IL-6-mediated STAT3 activation has been shown to promote drug resistance in cancer cells27, underscoring the importance of such cytokine signaling between stromal MFs and cancer cells as a possible target for cancer therapeutic development. This evidence concerns the gene STAT3 and cancer.